Contrasting the KIAA1549::BRAF and V600E groups
| Variable | Overall N=25 |
KIAA1549::BRAF
N=8 |
V600E
N=17 | P value | q-value* |
| Age | 19.16 (average) | 6.74 (average) | 25.01 (average) | <0.001† | 0.002 |
| Age group | 0.008† | 0.019 | |||
| <18 | 15/25 (60%) | 8/8 (100%) | 7/17 (41%) | ||
| ≥18 | 10/25 (40%) | 0/8 (0%) | 10/17 (59%) | ||
| Gender | 0.41 | 0.59 | |||
| Female | 12/25 (48%) | 5/8 (62%) | 7/17 (41%) | ||
| Male | 13/25 (52%) | 3/8 (38%) | 10/17 (59%) | ||
| Tumour size | 3.91 (average) | 5.16 (average) | 3.29 (average) | 0.025† | 0.050 |
| Tumour location | <0.001† | 0.002 | |||
| Hemispheric | 13/25 (52%) | 0/8 (0%) | 13/17 (76%) | ||
| Midline | 12/25 (48%) | 8/8 (100%) | 4/17 (24%) | ||
| Path diagnosis of PA | <0.001† | 0.002 | |||
| PA | 9/25 (36%) | 7/8 (88%) | 2/17 (12%) | ||
| Other | 16/25 (64%) | 1/8 (12%) | 15/17 (88%) | ||
| Path diagnosis of GBM | 0.53 | 0.66 | |||
| GBM | 3/25 (12%) | 0/8 (0%) | 3/17 (18%) | ||
| Other | 22/25 (88%) | 8/8 (100%) | 14/17 (82%) | ||
| Grade | 0.14 | 0.23 | |||
| Low | 20/25 (80%) | 8/8 (100%) | 12/17 (71%) | ||
| High | 5/25 (20%) | 0/8 (0%) | 5/17 (29%) |
*q-value estimates false discovery rate.
†Indicates statistical significance.
GBM, glioblastoma; PA, pilocytic astrocytoma.